Drug intelligence / Profile preview

Jin Lian Hua

Development stage
Unknown
Lead developer
Chengde Yushi Pharmaceutical
Modality
Small Molecules
Administration
Oral
01

Overview

Jin Lian Hua is a botanical drug product derived from the dried flowers of *Trollius chinensis* Bunge, a plant widely utilized in Traditional Chinese Medicine (TCM) for its "heat-clearing" and "detoxifying" properties. It is approved by the National Medical Products Administration (NMPA) of China for the treatment of upper respiratory tract inflammatory diseases, including pharyngitis, tonsillitis, and acute bronchitis. The pharmacological activity of the extract is primarily attributed to its rich content of flavonoids, such as orientin, vitexin, and quercetin, as well as organic acids. These constituents exhibit anti-inflammatory, antibacterial, and antiviral effects by modulating pro-inflammatory mediators and inhibiting the growth of common respiratory pathogens. The drug is commonly available in oral dosage forms such as capsules, tablets, and granules, and is manufactured by several prominent Chinese pharmaceutical companies, including Chengde Yushi Pharmaceutical.

Brand names
Jinlianhua
Other names
Trollius chinensisGlobeflowerJinlianhua JiaonangJinlianhua Capsules
02

Targets

TNFA (Tumor necrosis factor alpha (soluble))

Beyond the preview

Go deeper on Jin Lian Hua.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Jin Lian Hua.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call